Guido Hildebrandt
University of Rostock, Universitätsmedizin Rostock, Stanford University
Papers
14
Total Citations
451
H-Index
11
About
Guido Hildebrandt is a prominent radiation oncologist whose research has significantly advanced the field of stereotactic body radiotherapy (SBRT), with a particular focus on the treatment of liver and lung oligometastases as well as spinal radiosurgery. His most impactful contribution, a 2018 pooled analysis conducted through the German Society for Radiation Oncology (DEGRO) SBRT database initiative, examined outcomes across 474 patients and 623 liver metastases, earning 152 citations and establishing foundational benchmarks for patterns of care in this challenging clinical setting. Hildebrandt has been instrumental in refining robotic radiosurgery techniques, contributing extensively to motion-compensated delivery systems, inverse treatment planning methodologies, and dosimetric quality assurance—work that has drawn international recognition through multi-institutional benchmark trials. His investigations into GTV mean-dose optimization for both liver and lung tumors have provided clinicians with practical, evidence-based protocols that balance tumor control with toxicity reduction. Further distinguishing his portfolio, Hildebrandt has pioneered the use of post-therapeutic MRI morphologic alterations to validate in-vivo treatment accuracy, offering novel insight into dose-response relationships. Collectively, his body of work, spanning over 400 combined citations, reflects a sustained commitment to improving precision, safety, and outcomes in modern stereotactic radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3Treatment planning for spinal radiosurgery35 citations · 2018
- 4
- 5
- 6
- 7
- 8
- 9
- 10